Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Debt-to-Equity?

Great Novel Therapeutics Biotech & Medicals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$3.49 Mil. Great Novel Therapeutics Biotech & Medicals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$10.88 Mil. Great Novel Therapeutics Biotech & Medicals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$618.04 Mil. Great Novel Therapeutics Biotech & Medicals's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity or its related term are showing as below:

ROCO:7427' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.02
Current: 0.02

During the past 6 years, the highest Debt-to-Equity Ratio of Great Novel Therapeutics Biotech & Medicals was 0.02. The lowest was 0.00. And the median was 0.00.

ROCO:7427's Debt-to-Equity is ranked better than
87.74% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:7427: 0.02

Great Novel Therapeutics Biotech & Medicals Debt-to-Equity Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Debt-to-Equity Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					-	-	-	0.02	0.02

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity falls into.

Great Novel Therapeutics Biotech & Medicals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Great Novel Therapeutics Biotech & Medicals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.494	+	10.881)	/	618.036
	=	0.02

Great Novel Therapeutics Biotech & Medicals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.494	+	10.881)	/	618.036
	=	0.02

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Great Novel Therapeutics Biotech & Medicals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines